| --- | --- | --- | |--------------------------------|-------|-------------------------------| | | | | | | | | | $68M Cash & Cash Equivalents | | $225M Net Long-term Debt* | | ($8M) Operating Cash Flow (Q1) | | $8M Capital Expenditures (Q1) | De Novos Selective deployment to enable clinician and market growth Opened 3 de novos in Q1 Acquisitions 4 • Q1 Revenue of $252.6 million increased 24% year-over-year • Total clinicians of 5,961, +19% Y/Y; 330 net clinician adds in Q1 • Q1 Center Margin of $69.6 millio ...

LifeStance Health Group, Inc. (NASDAQ:LFST) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Monica Prokocki - Investor Relations Ken Burdick - Chief Executive Officer Dave Bourdon - Chief Financial Officer Danish Qureshi - Chief Operating Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Lisa Gill - JPMorgan Kevin Caliendo - UBS Jamie Perse - Goldman Sachs Brian Tanquilut - Jefferies Operator Good day, and welcome to the LifeStance Health First Quarter 2023 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40478 LifeStance Health Group, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 86-1832801 | | --- | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40478 LifeStance Health Group, Inc. (Exact name of Registrant as specified in its Charter) Delaware 86-1832801 (State or other jurisd ...

LifeStance Health Group, Inc. (NASDAQ:LFST) Q4 2022 Earnings Conference Call March 8, 2023 8:30 AM ET Company Participants Monica Prokocki - Vice President, Investor Relations Ken Burdick - Chief Executive Officer Dave Bourdon - Chief Financial Officer Danish Qureshi - Chief Operating Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Lisa Gill - JPMorgan Jack Senft - William Blair Brian Tanquilut - Jefferies Jamie Perse - Goldman Sachs Kevin Caliendo - UBS Operator Ladies and gentlemen, ...

LifeStance Health Group, Inc. (NASDAQ:LFST) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Monica Prokocki - Vice President of Investor Relations Ken Burdick - Chairman & Chief Executive Officer Mike Bruff - Chief Financial Officer Danish Qureshi - President & Chief Operating Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Lisa Gill - JP Morgan Brian Tanquilut - Jefferies Jack Senft - William Blair Jamie Perse - Goldman Sachs Operator Ladies and gent ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40478 LifeStance Health Group, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 86-1832801 (State or othe ...

LifeStance Health Group, Inc. (NASDAQ:LFST) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Monica Prokocki - Vice President of Investor Relations Mike Lester - Chief Executive Officer Danish Qureshi - Chief Growth Officer Mike Bruff - Chief Financial Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Lisa Gill - JPMorgan Stephanie Schiller Wissink - Jefferies Jack Senft - William Blair Kevin Caliendo - UBS Jamie Perse - Goldman Sachs Operator Good afternoo ...

Commission File Number: 001-40478 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) LifeStance Health Group, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 86-1832801 (State or other jur ...

Q1 2022 Earnings Presentation May 9, 2022 Forward-Looking Statements DISCLAIMERS Cautionary Note Regarding Forward-Looking Statements This presentation and related oral statements contain forward-looking statements about LifeStance Health Group, Inc. and its subsidiaries ("LifeStance") and the industry in which LifeStance operates, including statements regarding full-year and second quarter guidance, future results of operations and financial position of LifeStance, which are subject to known and unknown un ...